 |
 |
|
|
|
| Imatinib mesylate |
 |
| N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}nicotinamide methanesulfonate |
 |
| 220127-57-1 |
 |
Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec® (USA) or Glivec® (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally still referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of simply inhibiting rapidly dividing cells.
Imatinib mesylate is a white to off-white to brownish or yellowish tinged crystalline powder. Its molecular formula is C29H31N7O · CH4SO3 and its molecular weight is 589.7. Imatinib mesylate is soluble in aqueous buffers < pH 5.5 but is very slightly soluble to insoluble in neutral/alkaline aqueous buffers. In non-aqueous solvents, the drug substance is freely soluble to very slightly soluble in dimethyl sulfoxide, methanol and ethanol, but is insoluble in n-octanol, acetone and acetonitrile.
|
 |
Imatinib free base [CAS# 152459-95-5] & Intermediates
4-[(4-Methyl-1-piperazinyl)methyl]benzoic acid dihydrochloride hemihydrate
Cas number: 106261-49-8
4-(4-methylpiperazinomethyl)benzoyl chloride dihydrochloride
4-(chloromethyl)-N-4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenylbenzamide
Cas number: 404844-11-7, (404844-10-6 for HCl salt)
N-(5-Amino-2-methyl phenyl)-4-(3-pyridyl)-2-pyrimidineamine
Cas number: 152460-10-1
N-(2-methyl-5-nitrophenyl)-4-(3-pyridyl)-2-pyrimidineamine
Cas number: 152460-09-8
2-dimethylamino-1-(3-pyridyl)-2-propene-1-one
Cas number: 55314-16-4 (unspec), 75415-01-9 (Z), 123367-26-0 (E)
2-Methyl-5-nitro phenyl guanidine nitrate
Cas number: 152460-08-7, (152460-07-6 for free base)
|
|
|
|
|
|
